The worldwide sleep apnea device market has demonstrated moderate growth from $3.6 billion in 2011 to $4.2 billion in 2013, according to Kalorama Information, a division of The healthcare market research publisher said that undiagnosed cases and new devices will drive market growth. The estimate was calculated in Kalorama’s recent report on the respiratory device industry: “The Worldwide Market for Respiratory Devices.”

The report says it is likely that there will be device alternatives to CPAP on the horizon in the near future and the large sleep companies have made acquisitions to broaden their therapeutic offerings. For example, ResMed acquired Narval SA, a manufacturer of a mandibular repositioning device, and Philips Respironics acquired Aspire Medical, which was running clinical trials on a minimally invasive implant for sleep apnea caused by tongue obstruction.

“Sleep apnea is very common, as common as adult diabetes,” says Mary Ann Crandall, analyst for Kalorama Information and the author of the report, in a release. “Yet still because of the lack of awareness by the public and healthcare professionals, the vast majority remain undiagnosed and therefore untreated.”